Research News and Research

RSS

GlaxoSmithKline, Pfizer formally launch company to develop new HIV treatments

Pharmaceutical companies GlaxoSmithKline (GSK) and Pfizer on Tuesday formally launched ViiV Healthcare, a company focused on the development of new HIV treatments, Dow Jones Newswires/SmartMoney.com reports (11/3).

3 Nov 2009

$3.9 million Challenge grant for Thomas Jefferson researchers

Four researchers from Thomas Jefferson University have received $3.9 million in Challenge grant funds as part of the American Recovery and Reinvestment Act.

3 Nov 2009

Health affairs issue focuses on HIV/AIDS, NTDs

By 2031 developing countries could need an estimated $35 billion to fight HIV/AIDS - three times the amount currently spent, according to a Health Affairs study published Tuesday, the New York Times reports.

3 Nov 2009

Aethlon Medical begins collaborative biomarker program to study neurodegenerative disease

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has initiated a collaborative biomarker discovery program with the Center for the Study of Traumatic Encephalopathy (CSTE) at Boston University School of Medicine and the Sports Legacy Institute (SLI).

3 Nov 2009

Scientists discover two genes that can lead to aggressive leukaemia

Two genes, each one of which is known to cause cancer on its own, together can lead to aggressive leukaemia. This is the conclusion from new research carried out on gene-modified mice at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The discovery has surprised scientists, and may lead to new treatments.

3 Nov 2009

Entest BioMedical and Quantum Advisors sign Letter of Intent

Entest BioMedical Inc. (OTCBB: ENTB) announced today that it has signed a Letter of Intent with Quantum Advisors, a San Diego based biotechnology consulting firm, to assist Entest with the development of its Stem Cell Therapeutic Treatment for Chronic Obstructive Pulmonary Disease (COPD).

3 Nov 2009

Business groups begin TV ad campaign against House health bill

Lobbying and business groups continue to organize and spend millions to shape health care reform.

3 Nov 2009

Christian Science Monitor examines focus on combatting hunger

The Christian Science Monitor looks at one idea about why hunger is receiving a lot of attention in the international arena. Kanayo Nwanze, the Kenyan "who recently became president of the United Nations' International Fund for Agricultural Development (IFAD) says globalization has made the hunger and rural poverty that always pulled on the heartstrings an international security issue," according to the publication.

3 Nov 2009

Financial results for third-quarter 2009 announced by Combinatorx

CombinatoRx, Incorporated today reported financial results for the third quarter ended September 30, 2009.

3 Nov 2009

Exact Sciences announces financial results for the third quarter ended Sept. 30, 2009

Exact Sciences Corp. today announced its financial results for the third quarter ended Sept. 30, 2009.

3 Nov 2009

Arrowhead Research updates its shareholders

Arrowhead Research Corporation’s (NASDAQ: ARWR) President and Chief Executive Officer today issued the following letter to the Company’s shareholders.

3 Nov 2009

Hetero bags 4 million dollar contract from Hard to Treat Diseases

Hard to Treat Diseases (HTDS; http://www.htdsmedical.com) Mellow Hope operating subsidiary is in process of finalizing contract details with Hetero Ltd., www.heterodrugs.com one of the largest pharmaceutical manufacturers in India. This contract has been in the works since March 2009, and its finalization promises solid sales boost for Hard to Treat Diseases.

3 Nov 2009

NIH awards Trevena $7.65M Grand Opportunity grant

Trevena Inc., a leader in the discovery of G-protein coupled receptor (GPCR) biased ligands announced today that it was awarded a $7.65 million Grand Opportunity (GO) Grant by the office of the director of the National Institutes of Health (NIH). This grant will further fund Trevena’s work to identify and characterize functionally selective biased ligands for a wide range of GPCRs.

3 Nov 2009

NIH awards $4 million research grant to AllTranz

AllTranz, Inc., a specialty pharmaceutical company focused on developing drugs to treat a variety of neurologic and inflammatory disorders, today announced that it has been awarded a $4 million research grant from the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), to advance the company’s transdermal tetrahydrocannabinol (THC) patch for the treatment of marijuana dependence and withdrawal.

3 Nov 2009

Akonni Biosystems announces worldwide launch of their TruTip product line

Akonni Biosystems, a molecular diagnostic (MDx) company focused on providing rapid and highly scalable solutions for research and infectious disease testing, today announced the worldwide launch of their TruTip product line for extracting DNA and RNA from samples with volumes ranging from 100 µl to 1000 µl or more.

3 Nov 2009

Researchers identify part of the brain that responds to both facial and vocal expressions of emotion

Researchers at the University of York have identified a part of the brain that responds to both facial and vocal expressions of emotion.

3 Nov 2009

Acorda Therapeutics' financial results for the third quarter of 2009 and update on Fampridine-SR

Acorda Therapeutics, Inc. today announced its financial results for the third quarter of 2009.

3 Nov 2009

Caucasian women may suffer from RLS up to four times more than African-American women

New research shows that Caucasian women may suffer from restless legs syndrome (RLS), a sleep disorder characterized by the strong urge to move the legs, up to four times more than African-American women. The study, presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that, overall, non-African-American (NAA) patients experienced RLS four times more often than African-Americans (AA).

3 Nov 2009

Risk of postoperative visual loss is highest after heart surgery

Imagine waking up after surgery to find out you have lost your sight—permanently. Although rare, postoperative visual loss is a well-recognized complication of anesthesia and surgery that is more common after certain types of procedures and in some groups of patients, according to a study in the November issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

3 Nov 2009

Texas State University researchers to evaluate the effects of ALKA-V6 on animal organisms

Texas State University and Orizon Research Institute announced the signing of an agreement today that will permit University Researchers to continue efforts through in vivo testing to further determine the potential and effectiveness of ALKA-V6, a compound which has shown remarkable ability to kill cancer cells and inhibit the HIV virus in laboratory experiments.

3 Nov 2009